Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (1886)	6/26/1998 4:08:00 PM
From: Profiteer	Read Replies (2) \| Respond to of 5402

Call the Freaking doctor yourself Andrew!! But be sure to report back ACCURATELY!! Thank you.

To: Andrew H who wrote (1886)	6/27/1998 12:32:00 AM
From: drdan	Read Replies (3) \| Respond to of 5402

Andrew, could you please tell us why it is so important to know the specific timetable for the applications. As long as the drug gets thru Phase One testing without any surprises about toxicity, pharm firms will be falling over themselves to buy into this company....the only difference from one application to the next will be the dosage administered; the drug will be structurally identical. Further, we have some data at varying doses that shows promising resuts for safety and efficacy............I think I'd be more concerned with Phase one and two testing for the near term....IMO.. good night